Apeloa Pharmaceutical Co.,Ltd
000739
Rang in aandelen
#4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aandeelprijs
$3.13
Marktkapitalisatie
$3.62B
Verandering (1 dag)
-1.42%
Verandering (1 jaar)
46.59%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)
Categorie
Healthcare
P/B-ratio voor Apeloa Pharmaceutical Co.,Ltd (000739)
P/B-ratio op October 2026 TTM: 3.59
Volgens de meest recente financiële rapporten en aandelenkoers van Apeloa Pharmaceutical Co.,Ltd is de huidige P/B-ratio (TTM) 3.59. Eind 2024 had het bedrijf een P/B-ratio van 2.79.
P/B-ratiohistoriek voor Apeloa Pharmaceutical Co.,Ltd van 2000 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.59 | 21.27% |
| 2025 | 2.96 | 5.96% |
| 2024 | 2.79 | -4.02% |
| 2023 | 2.91 | -36.30% |
| 2022 | 4.57 | -44.09% |
| 2021 | 8.17 | 30.79% |
| 2020 | 6.25 | 54.03% |
| 2019 | 4.06 | 55.35% |
| 2018 | 2.61 | 6.58% |
| 2017 | 2.45 | -25.52% |
| 2016 | 3.29 | -15.47% |
| 2015 | 3.89 | 8.52% |
| 2014 | 3.59 | 61.94% |
| 2013 | 2.21 | 84.56% |
| 2012 | 1.20 | -71.82% |
| 2011 | 4.26 | 43.16% |
| 2010 | 2.97 | -10.68% |
| 2009 | 3.33 | 131.56% |
| 2008 | 1.44 | -62.40% |
| 2007 | 3.82 | 20.96% |
| 2006 | 3.16 | 103.63% |
| 2005 | 1.55 | -23.64% |
| 2004 | 2.03 | -11.01% |
| 2003 | 2.29 | -41.50% |
| 2002 | 3.91 | -43.69% |
| 2001 | 6.94 | 17.81% |
| 2000 | 5.89 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 1.9834 | -44.75% |
DE
|
|
| 2.1139 | -41.11% |
DE
|
|
| 1.3124 | -63.44% |
JP
|
|
| 6.3468 | 76.81% |
CH
|
|
| 5.041 | 40.43% |
IN
|
